Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Amri Stories

2014-04-16 08:34:19

ALBANY, N.Y., April 16, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it will be transitioning Discovery and Development Services (DDS) activities at its Syracuse, N.Y. site to other sites within AMRI and will cease operations in Syracuse by the end of June 2014. The actions taken today are consistent with AMRI's ongoing efforts to consolidate its facility resources to more effectively utilize its discovery and development resource pool and to further reduce its...

2014-04-04 16:23:47

ALBANY, N.Y., April 4, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals, Inc. Cedarburg, whose capabilities both augment and complement those of AMRI, is a contract developer and manufacturer of technically complex active pharmaceutical ingredients (API's) for both generic and branded customers. The transaction is consistent with AMRI's strategy to be the preeminent supplier of custom and...

2014-03-26 08:29:06

ALBANY, N.Y., March 26, 2014 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the Thirteenth Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 10:00 a.m. ET. A webcast of the presentation can be accessed at the Investor Relations' section of www.amriglobal.com, or at the following URL: http://wsw.com/webcast/needham65/AMRI/ The webcast will be...

2014-03-24 08:27:37

- Broadens Contract Development and Manufacturing Capabilities with High Value, Complex API Business - ALBANY, N.Y., March 24, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has signed a definitive agreement to acquire all the outstanding shares of Cedarburg Pharmaceuticals, Inc. for $38.2 million in cash. The transaction, including $2.8 million of assumed liabilities, is valued at $41 million. Cedarburg Pharmaceuticals is a contract developer and manufacturer of...

2014-02-27 08:29:49

ALBANY, N.Y., Feb. 27, 2014 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at Barclays Global Healthcare Conference on Wednesday, March 12, 2014 at 2:00 p.m. ET. A webcast of the presentation can be accessed at the Investor Relations' section of www.amriglobal.com, or at the following URL: http://cc.talkpoint.com/barc002/031114a_bc/?entity=74_YT6EEMI The webcast will be...

2014-02-12 08:29:05

Full Year 2013 Contract Revenue Growth of 11% to $210 Million and Adjusted Diluted EPS of $0.70 ALBANY, N.Y., Feb. 12, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2013. Fourth Quarter and Full Year 2013 Highlights: -- Full year adjusted diluted EPS increased by 280% to $0.70; exceeds guidance of $0.67 -- Fourth quarter adjusted diluted EPS increased by 29% to $0.22 --...

2014-01-29 08:30:03

ALBANY, N.Y., Jan. 29, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue fourth quarter and full year financial results before the opening of the market on Wednesday, February 12, 2014. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 10 a.m. ET. The conference call can be accessed by dialing 888-401-4669 (domestic calls) or 719-785-1753 (international calls) at 9:50 a.m. ET and entering passcode...

2014-01-10 08:23:41

Leadership Appointment Bolsters API Business and Leadership Team ALBANY, N.Y., Jan. 10, 2014 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) today announced the appointment of Vijay Kumar Batra, to the position of Managing Director, AMRI India, effective January 2, 2014. Mr. Batra will report to Steve Hagen, Ph.D., Senior Vice President of Manufacturing and Pharmaceuticals. "Mr. Batra brings a wealth of experience in the Active Pharmaceutical Ingredients (APIs) and...

2014-01-09 08:27:43

ALBANY, N.Y., Jan. 9, 2014 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, President and Chief Executive Officer at AMRI, will present at the 32(nd) Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 7:30 a.m. PT. A webcast of the presentation can be accessed at the Investor Relations' section of www.amriglobal.com, or at the following URL:...

2013-11-06 08:30:15

Third Quarter Contract Revenue up 16% at $53.0 Million and Adjusted Diluted EPS of $0.13 ALBANY, N.Y., Nov. 6, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the third quarter ended September 30, 2013. Financial highlights for the third quarter include: -- Adjusted diluted earnings per share of $0.13, compared to $0.00 in the prior-year period -- Contract revenue of $53.0 million, up 16% from the prior-year period --...